BrainsWay to Report First Quarter Financial Results on May 11, 2022
BrainsWay Ltd. (NASDAQ: BWAY) announced it will report its first-quarter financial results and operational highlights on May 11, 2022, before U.S. markets open. The company will host a conference call at 8:30 AM ET to discuss the results and provide business updates. BrainsWay specializes in advanced noninvasive neurostimulation treatments for mental health disorders and is known for its FDA-cleared Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, with indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
- BrainsWay is the first TMS company with three FDA-cleared indications.
- Current clinical trials are expanding Deep TMS applications in various disorders.
- None.
BURLINGTON, Mass. and JERUSALEM, April 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, May 11, 2022 |
| Time: | 8:30 AM Eastern Time |
| United States: | 877-407-3982 |
| International: | 201-493-6780 |
| Israel: | 1-809-406-247 |
| Conference ID: | 13729554 |
| Webcast: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=mHgZy2O9 |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
When will BrainsWay release its Q1 financial results?
What time is the BrainsWay conference call?
What are the FDA-cleared indications for BrainsWay's Deep TMS technology?
How can I access the BrainsWay conference call?
